Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation

American Journal of Transplantation

Volumn 11, Issue 12, 2011, Pages 2708-2714

  Gala Lopez, B L ^a   Senior, P A ^a,b   Koh, A ^a,b   Kashkoush, S M ^a   Kawahara, T ^a   Kin, T ^a   Humar, A ^b   Shapiro, A M J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytomegalovirus; immunosuppression; islet transplant; prophylaxis

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZ; DACLIZUMAB; ETANERCEPT; GANCICLOVIR; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; SEROLOGY; T CELL DEPLETION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CANADA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS, TYPE 1; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; INCIDENCE; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 82455212072     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03724.x     Document Type: Article

References (29)

1. Ryan EA, Bigam D, Shapiro AM,. Current indications for pancreas or islet transplant. Diabetes Obes Metab 2006; 8: 1-7.
2. Shapiro AM, Ricordi C, Hering BJ, et al,. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330. (Pubitemid 44465460)
3. Ryan EA, Paty BW, Senior PA, et al,. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069. (Pubitemid 40911269)
4. Barshes NR, Lee TC, Brunicardi FC, et al,. Lack of cytomegalovirus transmission after pancreatic islet transplantation. Cell Transplant 2004; 13: 833-838. (Pubitemid 40280222)
5. Freeman RB, Paya C, Pescovitz MD, et al,. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765-1773. (Pubitemid 40041643)
6. Humar A, Paya C, Pescovitz MD, et al,. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4: 644-649. (Pubitemid 38523588)
7. Humar A, Mazzulli T, Moussa G, et al,. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065-1070. (Pubitemid 40571255)
8. Huurman VA, Kalpoe JS, van de Linde P, et al,. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006; 29: 842-847. (Pubitemid 44115304)
9. Cure P, Pileggi A, Faradji RN, et al,. Cytomegalovirus infection in a recipient of solitary allogeneic islets. Am J Transplant 2006; 6 (Pt 1): 1089-1090. (Pubitemid 44356665)
10. Eckhard M, Martin I, Eich T, et al,. Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function. Transplant Proc 2002; 34: 1922-1924.
11. Hafiz MM, Poggioli R, Caulfield A, et al,. Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. Am J Transplant 2004; 4: 1697-1702. (Pubitemid 39312306)
12. Yakubovich N, Fung MA, Thompson DM,. Three cases of cytomegalovirus infection following pancreatic islet transplantation. Transplant Proc 2007; 39: 1599-1603. (Pubitemid 46907891)
13. Fiorina P, Shapiro AM, Ricordi C, Secchi A,. The clinical impact of islet transplantation. Am J Transplant 2008; 8: 1990-1997.
14. Shapiro AM, Lakey JR, Paty BW, et al,. Strategic opportunities in clinical islet transplantation. Transplantation 2005; 79: 1304-1307. (Pubitemid 40734790)
15. Ryan EA, Lakey JR, Paty BW, et al,. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 2148-2157. (Pubitemid 34729020)
16. Shapiro AM, Lakey JR, Ryan EA, et al,. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238. (Pubitemid 30490390)
17. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW,. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413-420. (Pubitemid 18096377)
18. O'Gorman D, Kin T, Imes S, Pawlick R, Senior P, Shapiro AM,. Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation 2010; 90: 255-259.
19. Barbaro B, Salehi P, Wang Y, et al,. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007; 84: 1200-1203. (Pubitemid 350125364)
20. Baidal DA, Froud T, Ferreira JV, Khan A, Alejandro R, Ricordi C,. The bag method for islet cell infusion. Cell Transplant 2003; 12: 809-813. (Pubitemid 37409747)
21. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620. (Pubitemid 38523584)
22. Pak CY, Eun HM, McArthur RG, Yoon JW,. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988; 2: 1-4.
23. Kaufman DB, Leventhal JR, Gallon LG, et al,. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001; 72: 1940-1945. (Pubitemid 34027868)
24. Zanone MM, Favaro E, Quadri R, et al,. Association of cytomegalovirus infections with recurrence of humoral and cellular autoimmunity to islet autoantigens and of type 1 diabetes in a pancreas transplanted patient. Transpl Int 2010; 23: 333-337.
25. Roep BO, Hiemstra HS, Schloot NC, et al,. Molecular mimicry in type 1 diabetes: Immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann N Y Acad Sci 2002; 958: 163-165. (Pubitemid 34592219)
26. Warnock GL, Kneteman NM, Ryan EA, et al,. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 1989; 2: 570-572. (Pubitemid 19213862)
27. Kaufman DB, Iii GW, Bruce DS, et al,. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3: 855-864. (Pubitemid 36827907)
28. Han D, Berman DM, Willman M, et al,. Choice of immunosuppression influences cytomegalovirus dnaemia in cynomolgus monkey (macaca fascicularis) islet allograft recipients. Cell Transplant 2010; 19: 1547-1561.
29. Report CITR,. Sixth Annual Report. Available at: www.citregistry.org/ 2009; accessed June 7, 2011.